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Abstract
Background: Wnt factors control cell differentiation through semi-independent molecular cascades known as the β-
catenin-dependent (canonical) and -independent (non-canonical) Wnt signalling pathways. Genetic and epigenetic 
alteration of components of the canonical Wnt signalling pathway is one of the primary mechanisms underlying colon 
cancer. Despite increasing evidence of the role of the non-canonical pathways in tumourigenesis, however, the 
underlying molecular mechanisms are poorly understood.
Results: Here we report that the receptor tyrosine kinase-like orphan receptor 2 (ROR2), a transmembrane receptor for 
Wnt factors that activates non-canonical pathways, is frequently repressed by aberrant promoter hypermethylation in 
human colon cancer cell lines and primary tumours. By restoring ROR2 activity in colon cancer cells harbouring ROR2 
promoter hypermethylation, we show that the role of ROR2 in colon cancer cells is mediated, at least in part, by 
canonical Wnt and that its epigenetic-dependent loss can be pro-tumourigenic.
Conclusions: Our data show the importance of epigenetic alterations of ROR2 in colon cancer, highlighting the close 
interconnection between canonical and non-canonical Wnt signalling pathways in this type of tumour.
Introduction
The receptor tyrosine kinase-like orphan receptor 2
(ROR2) is a transmembrane protein that belongs to a
conserved family of tyrosine kinase receptors involved in
many developmental processes, including chondrogene-
sis [1], osteoblastogenesis [2] and neural differentiation
[3]. Accordingly, ROR2 mutations in humans result in
dominant brachydactyly type B and Robinow syndrome
[4], two syndromes of altered development characterised
by short stature, brachydactyly, segmental defects of the
spine and dysmorphic facial appearance [5].
ROR2 exerts its role in cell differentiation primarily
through the Wnt signalling pathway [6]. This pathway is
comprised of a number of extracellular effectors, mem-
brane proteins, intracellular signal transducers and
nuclear gene regulators that transmit extracellular signals
to the nucleus as precise instructions for regulating spe-
cific genes [7]. When β-catenin participates in this cas-
cade, the signalling pathway is known as canonical Wnt.
Wnt effectors can also induce β-catenin-independent sig-
nals that make up the non-canonical Wnt signalling path-
way. Within the Wnt signalling pathway, the primary role
of ROR2 is to mediate WNT5A signals in a complex
manner that is still unclear. ROR2 was initially shown to
mediate WNT5A-dependent inhibition of canonical Wnt
signalling downstream of β-catenin stabilisation in 293
cells, at the level of TCF-mediated transcription [8].
ROR2 was subsequently shown to mediate WNT5A-
dependent JNK activation in regulating convergent
extension movements in Xenopus gastrulation [9], and is
also known to enhance WNT1 and antagonise WNT3
activities in osteoblastic cells [10]. In the H441 lung carci-
noma cell line, ROR2 positively modulates Wnt3a-acti-
vated canonical signalling [11].
The Wnt signalling pathway is central to cell differenti-
ation and cancer. Genetic and epigenetic alterations of
components of the canonical Wnt signalling pathway are
a primary mechanism of colon cancer development [7].
ROR2 is overexpressed in oral [12] and renal cancer [13],
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Page 2 of 9and in osteosarcoma [14]. ROR2 overexpression activates
JNK, a component of the non-canonical Wnt pathway,
and has pro-tumourigenic effects [13,14].
ROR2 also mediates inhibition of the β-catenin-depen-
dent Wnt signalling pathway [8,10,15]. Paradoxically, the
aberrant epigenetic repression of other Wnt inhibitors
such as WIF-1, DKK1, SFRP1 and SFRP2 directly pro-
motes tumourigenesis in colon cancer cells by promoting
constitutive Wnt signalling [7,16-18]. Indeed, the ROR2
extracellular ligand WNT5A, which inhibits the canoni-
cal Wnt signalling pathway in certain molecular contexts
[8], is also aberrantly repressed by promoter hypermethy-
lation in acute lymphoblastic leukaemia [19] and in colon
cancer [20], and its absence is tumourigenic in these
tumour types. As ROR2 mediates the inhibition of
canonical signalling by WNT5, we hypothesised that this
orphan receptor could also be a target of aberrant epige-
netic regulation in colon cancer. Here we report that
ROR2 is frequently repressed by promoter hypermethyla-
tion in colon cancer and that its loss can be protumouri-
genic in colon cancer.
Results
ROR2 promoter is frequently aberrantly hypermethylated 
in colon cancer
Analysis of the region 1.0 kb upstream and 0.5 kb down-
stream of the ROR2 transcriptional start site identified a
CpG island, suggesting a potential role for CpG methyla-
tion in the regulation of ROR2 expression. To study the
possible aberrant epigenetic regulation of ROR2 in colon
cancer, we used bisulphite sequencing of multiple clones
to determine the methylation status of a ROR2 promoter
DNA region of 315 bp that spans the ROR2 transcrip-
tional start point in healthy colon tissue, in vitro-growing
colonocytes and eight colon cancer cell lines (HCT116,
SW480, LOVO, HT29, HCT15, DLD1, COLO205 and
RKO) (Figure 1A). This showed that the ROR2 promoter
was completely unmethylated in non-tumourigenic colon
primary tissues and in vitro-growing colonocytes, whilst
it was densely hypermethylated in most cancer cell lines
analysed (HT29, HCT15, DLD1, COLO205 and RKO).
These results were confirmed using the 27K Illumina
Infinium methylation platform to study the DNA methy-
lation status of two CpG positions (located 465 bp
upstream and 322 bp downstream of the ROR2 transcrip-
tion start site, respectively) within the ROR2 CpG island
(Figure 1B) and using methylation-specific PCR (Figure
1C).
To determine whether ROR2 promoter hypermethyla-
tion is also a frequent in vivo event, we used methylation-
specific PCR to analyse 36 primary colon adenocarcino-
mas (Figure 1D). We detected methylation at the ROR2
promoter in 14 of the 36 tumours (38.8%), which con-
firmed that this is a common event in vivo.
Promoter DNA methylation-mediated ROR2 repression in 
colon cancer
To determine the role of the ROR2 promoter hypermeth-
ylation in gene expression, we used qRT-PCR and WB to
compare ROR2 mRNA and protein levels in healthy
colon epithelium and the HCT116 and SW480 cell lines,
which do not show ROR2 promoter hypermethylation,
with the HT29, HCT15, DLD1 and RKO lines, which
present dense DNA methylation at the ROR2 promoter
(Figure 2A). These experiments showed that ROR2
mRNA and protein were only detected in samples lacking
ROR2 promoter hypermethylation. Although they
showed dense ROR2 promoter hypermethylation, HT29
cells expressed residual levels of ROR2 mRNA, insuffi-
cient to detect ROR2 protein. To study the relationship
between ROR2 promoter hypermethylation and ROR2
repression in more detail, we analysed ROR2 mRNA lev-
els in colon cancer cell lines incubated with the demethy-
lating drug 5-aza-2-deoxycytidine (Figure 2B). Treatment
with this drug resulted in marked reactivation of ROR2 in
cell lines displaying ROR2 promoter hypermethylation
(HCT15, DLD1 and RKO), but not in those lacking
hypermethylation (HCT116 and SW480) (Figure 2B).
This implies that in vitro ROR2 promoter hypermethyla-
tion is directly associated with ROR2 repression.
To study the relationship between ROR2 promoter
hypermethylation and gene expression in vivo, we analy-
sed ROR2 mRNA levels and used tissue microarrays to
determine the levels of ROR2 protein in 20 pairs of nor-
mal and tumour colon tissues obtained from the same
patients (Figures 2C, D). At the mRNA level, in 18 of the
20 paired samples analysed, ROR2 was much less strongly
expressed in tumour tissues than in their normal counter-
parts; mean ROR2 expression was seven times higher in
colon epithelium than in colon tumours (Figure 2C). At
the protein level, we also observed lower ROR2 levels in
tumour samples in most cases; we only detected positive
ROR2 staining in 35% of the colorectal tumours analysed
(Figure 2D). To determine the relationship between
ROR2 promoter hypermethylation with mRNA and pro-
tein expression, we selected three tumours that expressed
and three that did not express ROR2 mRNA, and analy-
sed the methylation status of the ROR2 promoter by
methylation-specific PCR (Figure 2E) and ROR2 protein
levels by WB. The results confirmed that tumours lacking
ROR2 expression presented promoter hypermethylation
and lack ROR2 protein. This corroborated a relationship
between ROR2 promoter hypermethylation and gene
repression in vivo. The data indicate that ROR2 promoter
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repression in colon cancer, both in vitro and in vivo.
Aberrant ROR2 promoter hypermethylation can promote 
tumourigenesis in colon cancer cells
To evaluate the functional role of ROR2 repression by
promoter hypermethylation in colon cancer, we trans-
fected ROR2 in the colon cancer cell line DLD1, which
shows DNA methylation-dependent ROR2 inactivation
(Figure 3A). MTT analysis of the effects of ROR2 restora-
tion on cell proliferation showed that ROR2 restoration
induced a notable reduction in DLD1 cell proliferation
(Figure 3B). We used colony-formation assays to further
characterise the role of ROR2 in the growth of colon can-
cer cells, and found that restoration of ROR2 activity
resulted in a 30% reduction in colony formation in DLD1
cells (Figure 3C). We also knocked down ROR2 expres-
sion by RNA interference in a ROR2-expressing colon
cancer cell line unmethylated at the ROR2 CpG island,
SW480. Reduced ROR2 expression (Fig. 3D) was associ-
ated with increased cell growth (Fig. 3E).
To study the in vivo role of ROR2 in colon carcinogene-
sis, we subcutaneously injected DLD1 cells with restored
ROR2 expression and isogenic controls transfected with
empty vectors into a cohort of immunodeficient nude
mice (Figure 3F). In both cases, macroscopic tumours
were observed 13 days after injection (Figure 3F). Resto-
ration of ROR2 expression in DLD1 cells resulted in a
marked reduction of tumour formation in vivo; at the
time the mice were sacrificed, DLD1 tumours expressing
ROR2 had on average half the volume of those lacking
ROR2 activity (Figure 3F). This in vivo evidence links
Figure 1 Aberrant ROR2 hypermethylation in colon cancer. (A) The ROR2 promoter with its associated CpG island (top). CpG location, transcription 
start site (TSS) and ATG are indicated. Bisulphite sequencing primers, white arrows; Illumina Infinium probes (465 bp upstream and 322 bp down-
stream of the TSS), red and green lines, respectively. Lower panels show bisulphite genomic sequencing results of 12 individual clones in healthy colon 
epithelium, colonocytes and eight colon cancer cell lines (HCT116, SW480, LOVO, HT29, HCT15, DLD1, COLO205 and RKO), showing methylated (black 
squares) or unmethylated cytosines (white squares). (B) DNA methylation analysis of two CpG sites within the ROR2 promoter in healthy colon epithe-
lium, colonocytes and eight colon cancer cell lines using Infinium methylation arrays. Relative methylation for each CpG site (-465 bp and + 322 bp) 
is represented on a scale from 0.0 to 1.0 (corresponding to a 0% and 100% likelihood of CpG hypermethylation). (C) Methylation-specific PCR (MSP) of 
ROR2 promoter in healthy colon tissue and colon cancer cell lines. A PCR band in lanes M or U indicates methylated or unmethylated genes, respec-
tively. In vitro-methylated DNA (IVD) was used as a positive control for methylated DNA. (D) Methylation analysis of the ROR2 promoter using MSP of 
36 primary colon tumours. Percentage of tumours with ROR2 promoter hypermethylation (unmethylated, white; methylated, red; top) and ethidium 
bromide staining of an MSP reaction of two representative tumours (unmethylated and methylated) resolved in an agarose gel (bottom).
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Figure 2 Promoter methylation-dependent ROR2 repression in colon cancer. (A) qRT-PCR analysis of ROR2 mRNA relative to GAPDH in three 
samples with unmethylated ROR2 (white) and four samples with ROR2 promoter hypermethylation (red; top panel). The bottom panel shows WB anal-
ysis of ROR2 and actin in normal colon epithelium. Two samples show unmethylated ROR2 (HCT116, SW480) and four samples show ROR2 promoter 
hypermethylation (HT29, HCT15, DLD1, RKO). (B) Relative ROR2 mRNA levels in two cancer cell lines with unmethylated ROR2 (white) and three sam-
ples with ROR2 promoter hypermethylation (red) after treatment with the demethylating drug 5-aza-2'-deoxycytidine. (C) qRT-PCR analysis of ROR2 
mRNA in 20 primary colorectal tumours and the corresponding normal colon epithelium. Results are shown as the mean ± SD of three independent 
experiments. (D) Immunohistochemistry analysis of ROR2 in formalin-fixed, paraffin-embedded tissues. The images show protein expression in col-
orectal gland mucosa (arrow) in normal colon epithelium and lack of ROR2 expression in a poorly differentiated colon adenocarcinoma. (E) Relation-
ship between ROR2 expression and promoter hypermethylation. qRT-PCR quantification of ROR2 relative to GAPDH expression in three ROR2-
expressing tumours (U1-3) and three tumours with low ROR2 expression (M1-3; left panel). MSP analysis of ROR2 promoter methylation. A PCR band 
in lanes M or U indicates methylated or unmethylated, respectively. IVD is used as a positive control for methylated DNA and normal lymphocytes (NL) 
as negative control (upper right). WB analysis of ROR2 protein expression in the same tumour samples (lower right).
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Page 5 of 9ROR2 aberrant promoter hypermethylation with colon
cancer development.
Canonical Wnt mediates the functional role of aberrant 
ROR2 promoter hypermethylation in colon cancer cells
Epigenetic repression of other Wnt pathway components
promotes tumourigenesis by the constitutive activation of
canonical Wnt [7]. In addition, ROR2 regulates TCF-
mediated transcription [8]. We thus hypothesised that
the role of ROR2 in colon cancer is mediated by canonical
Wnt signalling. To test this possibility, we tested whether
its restoration interfered with β-catenin/TCF-dependent
transcription, using luciferase reporter assays to analyse
the effect of exogenous ROR2 expression in ROR2-
silenced DLD-1 cells (Figure 4A). Restoration of ROR2
expression reduced basal β-catenin/TCF-dependent tran-
scription in DLD1 cells by 50%, suggesting that the role of
aberrant epigenetic repression of ROR2 in colon cancer is
mediated, at least in part, by canonical Wnt signalling.
ROR2 is reported to mediate the WNT5A-dependent
inhibition of β-catenin-TCF-regulated genes in human
embryonic cells [8,15]. To determine whether the canoni-
cal Wnt-dependent role of aberrant epigenetic repression
of ROR2 in colon cancer is WNT5A-associated, we used
we used a dual approach: i) we increased extracellular lev-
els using recombinant WNT5A protein and ii) we used
anti-WNT5A antibody to greatly reduce WNT5A activity
in DLD1 cells expressing ROR2 and control cells. We
studied the effect of WNT5A modulation on cell growth
and the Wnt signalling pathway. MTT assays showed
that, independently of ROR2 expression, WNT5A
removal reduced cell growth (Figure 4B, top). The
decrease in cell growth was greater in DLD1 cells that did
not express ROR2, although the difference was not signif-
icant (p = 0.12). Addition of recombinant WNT5A to cul-
ture medium had no relevant effect on cell growth,
independently of ROR2 expression (Figure 4B, bottom).
To study the effect of WNT5A modulation on canoni-
cal Wnt signalling, we treated ROR2-expressing DLD1
cells or control DLD1 cells with anti-WNT5A antibody
or with recombinant WNT5A. We determined nuclear β-
catenin levels in immunofluorescence experiments (Fig-
ure 4C) and analysed β-catenin/TCF-dependent tran-
scription in luciferase reporter assays (Figure 4D).
Figure 3 Restoration of ROR2 expression impairs tumour growth in vitro and in vivo. The effect of ROR2 restoration was studied in the DLD1 
colon cancer cell line. (A) WB showing restoration of ROR2 after transfection with the pcDNA3.1-ROR2-Flag construct; anti-Flag antibody was used. (B) 
MTT analysis of cell viability in DLD1 mock-(squares) and ROR2-Flag-transfected (circles) cells. (C) Colony formation assay of DLD1-transfected cell line. 
DLD1 mock-and ROR2-Flag-transfected cells were seeded in six-well plates and cultured for two weeks, when colonies were visible. Colony number 
is expressed relative to number of cells seeded. (D) Quantitative RT-PCR analysis of ROR2 mRNA relative to GAPDH in the SW480 cell line transfected 
with a control siRNA (control iRNA) or a ROR2-specific siRNA (ROR2 iRNA). (E) MTT analysis of viability in SW480 cells expressing ROR2 (control iRNA, 
squares) or ROR2 knocked-down (ROR2 iRNA, circles). (F) Effect of restoration of ROR2 expression on in vivo tumour growth. Mouse xenograft model, 
in which DLD1 mock-transfected cells were injected subcutaneously into the left flank and ROR2-transfected cells into the right flank of athymic nude-
Foxn1nu/un mice; representative images are shown (left). The right panels shows quantification of tumour size (cm3) in the mouse xenograft model; 
DLD1 mock-(circles) and ROR2-transfected cells (squares). (** p = < 0.01).
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Page 6 of 9Increasing or decreasing extracellular WNT5A levels had
little impact on β-catenin nuclear location and β-catenin/
TCF-dependent transcription (Figure 4C and 4D), sug-
gesting that the canonical Wnt-dependent role of ROR2
epigenetic deregulation in DLD1 colon cancer cells does
not necessarily require WNT5A.
Discussion
We report that the receptor tyrosine kinase-like orphan
receptor 2 (ROR2), a transmembrane protein that partici-
pates in Wnt signalling, is frequently repressed by aber-
rant promoter hypermethylation in human colon cancer.
In addition, we demonstrate that the epigenetic-depen-
dent loss of ROR2 can promote tumour growth in colon
cancer cells. This effect can be mediated, at least in part,
by the canonical Wnt signalling pathway, since restora-
tion of ROR2 activity in DLD1 colon cancer cells induced
a decrease in β-catenin/TCF-dependent transcription.
ROR2 is reported to have oncogenic properties in other
tumour types such as oral cancer [12], renal cancer [13]
and osteosarcoma [14]; it is frequently overexpressed in
these tumours, and its suppression in renal cancer cells
inhibits cell migration and growth in orthotopic xeno-
graft models [13]. In osteosarcoma cells, suppressed
expression of ROR2 (or its extracellular effector,
WNT5A) inhibits cell invasiveness and decreases invado-
podium formation [14].
These lines of evidence suggest that the role of ROR2 in
cancer is complex and that it can either promote or sup-
press tumour formation, depending on tumour type and
Figure 4 Wnt-dependent role of ROR2 in colon cancer cells. (A) Restoration of ROR2 inhibits β-catenin/TCF transcription activity. DLD1 colon can-
cer cells were transiently transfected with TOPflash or FOPflash reporters alone (white) or in the presence of different amounts of an ROR2 expression 
construct (black). Cells were lysed 48 h post-transfection and Firefly and Renilla luciferase activities measured. Results are shown as means ± SD of trip-
licate samples from one representative experiment. (B) WB showing ROR2 expression in DLD1 mock-and ROR2-transfected cells (left). MTT analysis of 
viability of the same cells in the presence of anti-WNT5A antibody (2 μg/ml; upper right) or recombinant WNT5A (200 ng/ml; lower right). Treatment 
was renewed daily. Data are expressed as the percent MTT signal relative to the untreated sample at the same time point. (C) Immunofluorescence 
staining of β-catenin and α-lamin B in DLD1 mock-and ROR2-transfected cells after 2 h treatment with recombinant WNT5A (200 ng/ml) or anti-
WNT5A antibody (2 μg/ml) or untreated (CTR). (D) TOPflash assay (as in A) of the same cells after 72 h treatment (as in B) with recombinant WNT5A or 
anti-WNT5A antibody.
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Page 7 of 9molecular context. A possible explanation for this com-
plexity could be the multifaceted role of ROR2 in the Wnt
signalling pathway. On the one hand, ROR2 can mediate
WNT5A-dependent activation of JNK, a member of the
non-canonical Wnt pathway in mice [9,21], while on the
other, ROR2 can govern the WNT5A-dependent inhibi-
tion of canonical Wnt signalling downstream of β-catenin
stabilisation [8]. Depending on the tumour type, ROR2
signals can therefore show a preference for β-catenin/
TCF-dependent genes or for non-canonical Wnt path-
ways. Two lines of evidence support these possibilities:
first, the pro-tumourigenic role of ROR2 in renal cancer
and osteosarcoma is thought to be mediated by activation
of the non-canonical Wnt signalling kinase JNK [13,14],
and second, in colon cancer cells with constitutive Wnt
signalling activity, restoration of ROR2 activity increased
the inhibition of β-catenin reporter genes (our data and
[15]).
As ROR2 is reported to mediate the WNT5A-depen-
dent inhibition of β-catenin-TCF-regulated genes in
human embryonic cells [8,15], we tested whether
WNT5A mediated the canonical Wnt-dependent role of
aberrant epigenetic ROR2 repression in colon cancer. We
evaluated the effect of increased or decreased extracellu-
lar WNT5A levels on cell growth and canonical Wnt
pathway status in ROR2-expressing DLD1 cells and con-
trols. Although modulation of extracellular WNT5A lev-
els affected cell growth, this effect was little influenced by
ROR2 expression. The canonical Wnt pathway did not
appear to be the effector of WNT5A modulation in these
cells. Our data thus suggest that the canonical Wnt-
dependent role of ROR2 hypermethylation in colon can-
cer cells does not necessarily require WNT5A. As
WNT5A might have canonical and non-canonical
effects, WNT5A/ROR2 could have a role in colon cancer
through non-canonical Wnt signalling within certain
molecular contexts. This pathway is frequently altered in
other tumour types [12-14]. Our results nonetheless do
not rule out a role for WNT5A in colon cancer through
the canonical Wnt signalling pathway; indeed, WNT5A
inhibits β-catenin/TCF-dependent transcription in
HCT116 colon cancer cells [20].
As proposed for ROR2, WNT5A might also have either
a tumour-promoting or-suppressing role. Many studies
report a tumour-suppressing effect, and it is downregu-
lated in a number of cancers such as colorectal and ductal
breast cancer, neuroblastoma and leukaemia (reviewed in
[22]). As we show here for ROR2, WNT5A repression in
colon and haematopoietic tumours is mediated by aber-
rant promoter hypermethylation [19,20]. In contrast,
WNT5A also has a tumour-promoting role in cases such
as non-small-cell lung cancer, melanoma, breast, gastric,
pancreatic and prostate cancers (reviewed in [22]). As
ROR2 and WNT5A functions are intimately associated--
indeed, ROR2 knockout mice phenocopy most of altera-
tions seen in WNT5A knockout mice [23]--ROR2 and
WNT5A might also have parallel or complementary roles
in cancer. ROR2/WNT5A upregulation could be advan-
tageous to cancers driven by non-canonical Wnt signal-
ling, while their epigenetic downregulation would benefit
tumours, such as colon and haematopoietic cancers, that
are driven by canonical Wnt signalling.
Methods
Human cancer cell lines culture and treatments, and 
primary tumour samples
The eight human colon cancer cell lines (HCT116,
SW480, LOVO, HT29, HCT15, DLD1, COLO205 and
RKO) and healthy colonocytes were obtained from the
American Type Culture Collection. Cell lines were main-
tained in appropriate medium and treated with 2 μmol/L
5-aza-2'-deoxycytidine (Sigma) for 3 days for DNA dem-
ethylation, anti-WNT5A antibody (2 μg/ml; R&D) or
recombinant WNT5A (200 ng/ml; Millipore). We
obtained 36 primary colon tumours from the Spanish
National Cancer Research Centre Tumour Bank and 20
pairs of same-patient healthy and colon tumour tissue
from the Institute of Oncology of Asturias Tumour Bank.
The study was approved by the appropriate institutional
review boards.
DNA methylation analysis of the ROR2 gene
We established ROR2 CpG island methylation status by
PCR analysis of bisulphite-modified genomic DNA.
Methylation status was first analysed by bisulphite
genomic sequencing of the CpG island using primers: 5'-
GGG GTT TTA GTT GTA GTT TTA GT-3' (sense) and
5'-CTC CTC CTT CTC CCT AAC-3' (anti-sense).
Twelve independent clones were sequenced for each sam-
ple. The second analysis used methylation-specific PCR
with primers specific to the methylated or modified unm-
ethylated DNA. Primer sequences for the methylated
reaction were 5'- GTT TCG TTT TGT TTA TCG GGG
C - 3' (sense) and 5'-ACT AAA AAA ATT CCT TAA
CGC GAA -3' (anti-sense), and for the unmethylated
reaction 5'-GTT TTG TTT TGT TTA TTG GGG TGG-
3' (sense) and 5'-TAA CTA AAA AAA TTC CTT AAC
ACA AA-3' (anti-sense). In vitro-methylated DNA (IVD)
was used as a positive control for the methylated reaction.
PCR products were identified in ethidium bromide-
stained 2% agarose electrophoresis gels and viewed under
UV light. We designed the bisulphite genomic sequenc-
ing and methylation-specific PCR primers using Methyl
Primers Express software and confirmed bisulphite
sequencing and methylation-specific PCR results using
Illumina Infinium Methylation Arrays (Illumina). The
two CpG sites analysed were located 465 bp upstream
and 322 bp downstream of the ROR2 transcriptional start
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resented by a scale from 0.0 to 1.0 (corresponding to 0%
and 100% likelihood of gene promoter hypermethylation,
respectively).
ROR2 RNA and protein analysis by quantitative reverse-
transcription PCR and immunohistochemistry
Total RNA (1 μg) extracted with Trizol reagent (Invitro-
gen) was converted to cDNA using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems).
The PCR reaction was performed by mixing the con-
verted cDNA with the TaqMan Gene Expression Assay
for ROR2 (Hs00171695_m1 ROR2) and GAPDH
(Hs99999905_m1 GAPDH) and TaqMan Universal PCR
Master Mix (Applied Biosystems). qRT-PCR was per-
formed in the Applied Biosystems 7900 HT Fast Real-
Time PCR System. Data were normalised using GAPDH
as the endogenous control gene. The ROR2 protein was
analysed with an anti-ROR2 antibody (from Abcam for
immunohistochemistry; from Sigma for WB), following
standard procedures.
ROR2 transfection experiments
The pcDNA3.1-ROR2-Flag construct was created using a
pcDNA3.1-ROR2 plasmid (kindly provided by Dr J. Bil-
liard) as a template. The construct was confirmed by
DNA sequencing. Control cells were transfected using
the empty plasmid (mock). DLD1 cells were transfected
with the pcDNA3.1-ROR2-Flag plasmid or the empty
plasmid using Lipofectamine 2000 (Invitrogen). Stable
transfectants were obtained after 2 weeks selection with 1
mg/ml G418 (Calbiochem). ROR2-Flag expression was
confirmed by WB using anti-Flag antibody (1:2000,
Sigma).
Cell viability assay
Cell viability was determined as described [24]. Aliquots
(104 cells) were plated onto 96-well plates. After cell
attachment, MTT was added to medium (50 μg; 100 μl/
well) and incubated (3 h, 37°C, 5% CO2). MTT was
removed and MTT-formazan crystals were dissolved in
DMSO (100 μl/well). Absorbance at 595 nm was deter-
mined with an automated microtitre plate reader. Optical
density was directly proportional to cell number up to the
maximum density measured. Results are expressed as the
mean ± SD of at least five replicates and significance was
assessed by standard t-test.
Colony formation assay
Colony formation was assayed on ROR2-Flag-and mock-
transfected DLD1 cells. After 14 days selection, stable
G418-resistant colonies were fixed, MTT-stained, and
the mean number of colonies in each well was deter-
mined.
Mouse xenograft model
Five-week-old athymic Nude-Foxn1nu/nu mice (Charles
River) were used for tumour xenograft experiments with
ROR2-Flag-and mock-transfected DLD1 cells. Twelve
mice were used. Both flanks of each animal were injected
subcutaneously with 2 × 106 cells in 200 μl PBS; ROR2-
Flag-transfected cells were injected into the right flank
and empty vector cells into the left flank. Mice were
weighed, and tumour width (W) and length (L) were
measured every 5 days. Tumour volume was estimated
according to the formula V = 0.4. L.W2 (L = maximum
length; W = maximum width). Mice were killed 30 days
post-injection and tumours from both cell types were
excised and weighed. Mean volume and tumour mass ±
SEM were calculated for each group, and significant dif-
ferences were assessed by a two-tailed independent-sam-
ples t-test.
Transfection and reporter assays
Subconfluent cultures were transfected in triplicate using
JetPEI (PolyPlus Transfection, Illkirch, France) following
manufacturer's protocols. pTOPFLASH, and pFOP-
FLASH reporter plasmids have been described [25]. A
Renilla luciferase plasmid (pRL-TK) was used in all
experiments as an internal control. Firefly and Renilla
luciferase activities were measured separately using the
Dual Luciferase reagent kit (Promega, Madison, WI) and
a GloMax 96 microplate luminometer (Promega).
Immunofluorescence
ROR2-Flag-and mock-transfected DLD1 cells were meth-
anol-fixed and stained using mouse anti-β-catenin (Bec-
ton Dickinson) and goat anti-α-lamin B (Santa Cruz),
followed by Alexa448 donkey anti-goat IgG or Alexa594
donkey anti-mouse IgG (Molecular Probes).
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